Search

Your search keyword '"Montanaro, Marco"' showing total 79 results
Start Over Author "Montanaro, Marco"
79 results on '"Montanaro, Marco"'

51. Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycytemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up

Author

Andriani, Alessandro, primary, Latagliata, Roberto, additional, Cedrone, Michele, additional, Diveroli, Ambra, additional, Spirito, Francesca, additional, Ruscio, Carla, additional, Leonetti Crescenzi, Sabrina, additional, Porrini, Raffaele, additional, Di Giandomenico, Jonny, additional, Villivà, Nicoletta, additional, Spadea, Antonio, additional, Rago, Angela, additional, De Gregoris, Cinzia, additional, Pessina, Gloria, additional, De Muro, Marianna, additional, Felici, Stefano, additional, Breccia, Massimo, additional, Montefusco, Enrico, additional, Bagnato, Antonino, additional, Anaclerico, Barbara, additional, Cimino, Giuseppe, additional, Majolino, Ignazio, additional, Alimena, Giuliana, additional, and Montanaro, Marco, additional

Published
2014
Full Text
View/download PDF

52. Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients

Author

Montanaro, Marco, primary, Latagliata, Roberto, additional, Cedrone, Michele, additional, Spadea, Antonio, additional, Rago, Angela, additional, Di Giandomenico, Jonny, additional, Spirito, Francesca, additional, Porrini, Raffaele, additional, De Muro, Marianna, additional, Leonetti, Sabrina Crescenzi, additional, Villivà, Nicoletta, additional, De Gregoris, Cinzia, additional, Breccia, Massimo, additional, Montefusco, Enrico, additional, Santoro, Cristina, additional, Cimino, Giuseppe, additional, Majolino, Ignazio, additional, Mazzucconi, Maria Gabriella, additional, Alimena, Giuliana, additional, and Andriani, Alesssandro, additional

Published
2014
Full Text
View/download PDF

53. Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN)

Author

Latagliata, Roberto, primary, Montagna, Chiara, additional, Porrini, Raffaele, additional, Leonetti, Sabrina Crescenzi, additional, Niscola, Pasquale, additional, Ciccone, Fabrizio, additional, Spadea, Antonio, additional, Breccia, Massimo, additional, Rago, Angela, additional, Spirito, Francesca, additional, Cedrone, Michele, additional, De Muro, Marianna, additional, Montanaro, Marco, additional, Andriani, Alessandro, additional, Bagnato, Antonino, additional, Montefusco, Enrico, additional, Cimino, Giuseppe, additional, and Alimena, Giuliana, additional

Published
2013
Full Text
View/download PDF

54. The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?

Author

Latagliata, Roberto, primary, Montanaro, Marco, additional, Cedrone, Michele, additional, Villivà, Nicoletta, additional, Porrini, Raffaele, additional, Spirito, Francesca, additional, Rago, Angela, additional, Crescenzi, Sabrina Leonetti, additional, Spadea, Antonio, additional, De Muro, Marianna, additional, Cotroneo, Ettore, additional, Breccia, Massimo, additional, Baldacci, Erminia, additional, De Gregoris, Cinzia, additional, Anaclerico, Barbara, additional, Felici, Stefano, additional, Ruscio, Carla, additional, Giandomenico, Jonny Di, additional, Franceschini, Luca, additional, Pessina, Gloria, additional, Cimino, Giuseppe, additional, Montefusco, Enrico, additional, Tafuri, Agostino, additional, Avvisati, Giuseppe, additional, Majolino, Ignazio, additional, Mazzucconi, Maria Gabriella, additional, Alimena, Giuliana, additional, and Andriani, Alessandro, additional

Published
2012
Full Text
View/download PDF

55. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.

Author

Marcucci, Fabrizio, Mele, Alfonso, Spada, Enea, Candido, Angela, Bianco, Elvira, Pulsoni, Alessandro, Chionne, Paola, Madonna, Elisabetta, Cotichini, Rodolfo, Barbui, Anna, De Renzo, Amalia, Dore, Fausto, Iannitto, Emilio, Liso, Vincenzo, Martino, Bruno, Montanaro, Marco, Pagano, Livio, Musto, Pellegrino, Rapicetta, Maria, Pagano, Livio (ORCID:0000-0001-8287-928X), Marcucci, Fabrizio, Mele, Alfonso, Spada, Enea, Candido, Angela, Bianco, Elvira, Pulsoni, Alessandro, Chionne, Paola, Madonna, Elisabetta, Cotichini, Rodolfo, Barbui, Anna, De Renzo, Amalia, Dore, Fausto, Iannitto, Emilio, Liso, Vincenzo, Martino, Bruno, Montanaro, Marco, Pagano, Livio, Musto, Pellegrino, Rapicetta, Maria, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

In this hospital-based, multicenter case-control study we investigated the prevalence of hepatitis B virus (HBV)-related markers and HBV/hepatitis C virus (HCV) co-infection among B-cell non-Hodgkin’s lymphoma (B-NHL) cases and controls. Four hundred newly diagnosed B-NHL cases and 392 controls from other departments of the same hospitals were studied. The prevalence of positivity for hepatitis B surface antigen (HBsAg) was 8.5% among B-NHL cases and 2.8% among controls (adjusted odds ratio, 3.67; 95% confidence interval, 1.75-7.66). HBV/HCV co-infection was found in four cases, but in no controls. The finding of a positive association between HBV infection and BNHL raises the possibility that HBV may play an etiologic role in the induction of B-NHL.

Published
2006

56. Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the “Gruppo Laziale SMPC Ph Negative “,

Author

Montanaro, Marco, primary, Latagliata, Roberto, additional, Cedrone, Michele, additional, Villivà, Nicoletta, additional, Porrini, Raffaele, additional, Spirito, Francesca, additional, Rago, Angela, additional, Crescenzi, Sabrina Leonetti, additional, Spadea, Antonio, additional, De Muro, Marianna, additional, Cotroneo, Ettore, additional, Breccia, Massimo, additional, De Gregoris, Cinzia, additional, Anaclerico, Barbara, additional, Felici, Stefano, additional, Ruscio, Carla, additional, Di Giandomenico, Jonny, additional, Franceschini, Luca, additional, Pessina, Gloria, additional, Cimino, Giuseppe, additional, Montefusco, Enrico, additional, Majolino, Ignazio, additional, Mazzucconi, Maria Gabriella, additional, Alimena, Giuliana, additional, and Andriani, Alessandro, additional

Published
2011
Full Text
View/download PDF

57. Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea

Author

Latagliata, Roberto, primary, Cedrone, Michele, additional, Villivà, Nicoletta, additional, De Gregoris, Cinzia, additional, Breccia, Massimo, additional, Spadea, Antonio, additional, De Muro, Marianna, additional, Tafuri, Agostino, additional, Anaclerico, Barbara, additional, Felici, Stefano, additional, D'Andrea, Mariella, additional, Montefusco, Enrico, additional, Abruzzese, Elisabetta, additional, Spirito, Francesca, additional, Leonetti Crescenzi, Sabrina, additional, Recine, Umberto, additional, Mazzucconi, Maria Gabriella, additional, Annino, Luciana, additional, Cimino, Giuseppe, additional, Avvisati, Giuseppe, additional, Petti, Maria Concetta, additional, Alimena, Giuliana, additional, Montanaro, Marco, additional, and Andriani, Alessandro, additional

Published
2011
Full Text
View/download PDF

58. Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients

Author

Latagliata, Roberto, primary, Tafuri, Agostino, additional, Spadea, Antonio, additional, Ferretti, Antonietta, additional, Diverio, Daniela, additional, Breccia, Massimo, additional, D'Andrea, Mariella, additional, Andriani, Alessandro, additional, Montanaro, Marco, additional, Cedrone, Michele, additional, Montefusco, Enrico, additional, Rago, Angela, additional, Olimpieri, Odoardo Maria, additional, Bagnato, Antonino, additional, Biondo, Francesca, additional, Vozella, Federico, additional, Cantonetti, Maria, additional, Petti, Maria Concetta, additional, and Alimena, Giuliana, additional

Published
2011
Full Text
View/download PDF

60. A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloprolypherative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results

Author

Montanaro, Marco, primary, Latagliata, Roberto, additional, Montefusco, Enrico, additional, Cedrone, Michele, additional, Villivà, Nicoletta, additional, Cotroneo, Ettore, additional, Rago, Angela, additional, Spirito, Francesca, additional, De Muro, Marianna, additional, Breccia, Massimo, additional, Anaclerico, Barbara, additional, Porrini, Raffaele, additional, Pessina, Gloria, additional, Felici, Stefano, additional, Trapè, Giulio, additional, Tafuri, Agostino, additional, Mazzucconi, Maria Gabriella, additional, Cimino, Giuseppe, additional, Majolino, Ignazio, additional, Avvisati, Giuseppe, additional, Lo Coco, Francesco, additional, and Andriani, Alessandro, additional

Published
2010
Full Text
View/download PDF

61. Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features

Author

Latagliata, Roberto, primary, Cedrone, Michele, additional, Villivà, Nicoletta, additional, Breccia, Massimo, additional, Anaclerico, Barbara, additional, Volpicelli, Paola, additional, Ferretti, Antonella, additional, Felici, Stefano, additional, Montefusco, Enrico, additional, Abruzzese, Elisabetta, additional, Spadea, Antonio, additional, Spirito, Francesca, additional, Cotroneo, Ettore, additional, De Muro, Marianna, additional, Annino, Luciana, additional, Cimino, Giuseppe, additional, Alimena, Giuliana, additional, Montanaro, Marco, additional, and Andriani, Alessandro, additional

Published
2010
Full Text
View/download PDF

62. Evolution of Bisphosphonates RELATED Osteonecrosis of the Jaw (BRONJ) IN PATIENTS with MULTIPLE MYELOMA (MM) and WALDENSTROM'S Macroglobulinemia (WM): A Retrospective STUDY.

Author

Andriani, Alessandro, primary, Petrucci, Maria Teresa, additional, Caravita, Tommaso, additional, Montanaro, Marco, additional, Pisani, Francesco, additional, Coppetelli, Ugo, additional, De Muro, Marianna, additional, Bongarzoni, Velia, additional, Avvisati, Giuseppe, additional, Villivà, Nicoletta, additional, Levi, Anna, additional, Siniscalchi, Agostina, additional, Agrillo, Alessandro, additional, and Gaglioti, Domenico, additional

Published
2009
Full Text
View/download PDF

63. MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study.

Author

Offidani, Massimo, primary, Bringhen, Sara, additional, Corvatta, Laura, additional, Petrucci, Maria Teresa, additional, Gentili, Silvia, additional, Musto, Pellegrino, additional, Polloni, Claudia, additional, Gentilini, Fabiana, additional, Falcone, Antonietta, additional, Caravita, Tommaso, additional, Liberati, Anna Marina, additional, Brunori, Marino, additional, Callea, Vincenzo, additional, Piro, Eugenio, additional, Grasso, Mariella, additional, Cangialosi, Clotilde, additional, Galieni, Piero, additional, Rossini, Fausto, additional, Galli, Monica, additional, Montanaro, Marco, additional, Alesiani, Francesco, additional, Stefano, Valerio De, additional, Catarini, Massimo, additional, Elice, Francesca, additional, Zambello, Renato, additional, Visani, Giuseppe, additional, Griso, Luciano, additional, Angelucci, Emanuele, additional, Boccadoro, Mario, additional, Leoni, Pietro, additional, and Palumbo, Antonio, additional

Published
2009
Full Text
View/download PDF

64. Melphalan 200 Mg/m2 (Mel200) Versus Melphalan 100 Mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

Author

Boccadoro, Mario, primary, Bringhen, Sara, additional, Petrucci, Maria Teresa, additional, Falcone, Antonietta, additional, Liberati, Anna Marina, additional, Ria, Roberto, additional, Grasso, Mariella, additional, Montanaro, Marco, additional, Pregno, Patrizia, additional, Nozza, Andrea, additional, Pisani, Francesco, additional, Caravita, Tommaso, additional, Cangialosi, Clotilde, additional, Calabrese, Elisabetta, additional, Larocca, Alessandra, additional, Cavallo, Federica, additional, Ruggeri, Marina, additional, Musto, Pellegrino, additional, Foà, Robert, additional, and Palumbo, Antonio, additional

Published
2008
Full Text
View/download PDF

65. Evolution of Bisphosphonates Related Osteonecrosis of the Jaw (BRONJ) in Patients with Multiple Myeloma (MM): A Retrospective Study

Author

Andriani, Alessandro AA Alessandro, primary, Petrucci, Maria Teresa MTP, primary, Caravita, Tommaso, primary, Montanaro, Marco, primary, Pisani, Francesco, primary, Coppetelli, Ugo, primary, De Muro, Marianna, primary, Bongarzoni, Velia, primary, Avvisati, Giuseppe, primary, Villivà, Nicoletta, primary, Levi, Anna, primary, Siniscalchi, A., primary, Agrillo, Alessandro, primary, and Gaglioti, Domenico, primary

Published
2008
Full Text
View/download PDF

66. A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients.

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Petrucci, Maria Teresa, additional, Falcone, Antonietta, additional, Liberati, Anna Marina, additional, Lauta, Vito Michele, additional, Grasso, Mariella, additional, Montanaro, Marco, additional, Pisani, Francesco, additional, Caravita, Tommaso, additional, Cangialosi, Clotilde, additional, Pregno, Patrizia, additional, Nozza, Andrea, additional, Calabrese, Elisabetta, additional, Gay, Francesca, additional, Cavallo, Federica, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Foà, Robin, additional, and Boccadoro, Mario, additional

Published
2007
Full Text
View/download PDF

67. Role of Extracellular Signal-Regulated Kinase-1/2 (ERK) on Complete Remission Achievement of Primary Adult Acute Lymphoblastic Leukemia Patients Enrolled in the GIMEMA Protocol LAL 2000: In Vitro Activity of the MEK Inhibithor PD98059.

Author

Gregorj, Chiara, primary, Petrucci, Maria T., primary, Scerpa, Maria C., primary, Ricciardi, Maria R., primary, De Cave, Fabiana, primary, Gervasoni, Jacopo, primary, Vignetti, Marco, primary, Gubbiotti, Stefania, primary, Ariola, Cristina, primary, Specchia, Giorgina, primary, Chiarenza, Annalisa, primary, Ferrara, Felicetto, primary, Fabbiano, Francesco, primary, Camera, Andrea, primary, Fioritoni, Giuseppe, primary, Miraglia, Eustachio, primary, Annino, Luciana, primary, Mosna, Federico, primary, Cantore, Nicola, primary, Luppi, Mario, primary, Nobile, Francesco, primary, Leone, Giuseppe, primary, Depaoli, Lorella, primary, Peta, Antonio, primary, Martelli, Massimo A., primary, Majolino, Ignazio, primary, Montanaro, Marco, primary, Milella, Michele, primary, Meloni, Giovanna, primary, Foà, Robert, primary, and Tafuri, Agostino, primary

Published
2005
Full Text
View/download PDF

68. Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Author

Palumbo, Antonio, primary, Bringhen, Sara, primary, Musto, Pellegrino, primary, Caravita, Tommaso, primary, Capozzi, Rosanna, primary, Callea, Vincenzo, primary, Cangialosi, Clotilde, primary, Montanaro, Marco, primary, Catalano, Lucio, primary, Grasso, Mariella, primary, Petti, Maria Concetta, primary, Merla, Manuela, primary, Falchi, Lorenzo, primary, Omedè, Paola, primary, Ceccarelli, Manuela, primary, Ambrosini, Maria Teresa, primary, Avonto, Ilaria, primary, Gay, Francesca, primary, Falco, Patrizia, primary, and Boccadoro, Mario, primary

Published
2005
Full Text
View/download PDF

70. A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.

Author

Molica, Stefano, Mauro, Francesca, Callea, Vincenzo, Gentile, Massimo, Giannarelli, Diana, Lopez, Manuela, Lauria, Francesco, Rotoli, Bruno, Montanaro, Marco, Cortelezzi, Agostino, Liso, Vincenzo, Mandelli, Franco, and Foa, Robin

Subjects
MEDICAL research, LYMPHOCYTIC leukemia, CHRONIC diseases, CLINICAL medicine, CHRONIC lymphocytic leukemia, LYMPHOPROLIFERATIVE disorders
Abstract

To facilitate the development of a prognostic model for early B-cell chronic lymphocytic leukemia (CLL), the Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto (GIMEMA) proposes its multi-institutional effort as a working model. In total, 1138 newly diagnosed Binet stage A patients managed over the last 10 years outside the setting of clinical trials according to a “wait and see” policy form the basis of the present study aimed at investigating prognostic variables affecting disease progression, a surrogate endpoint for overall survival.A 3-stage risk system, simply obtained by summing the variables that proved significant in the multivariate analysis (i.e. short lymphocyte doubling time, advanced Rai substage, high peripheral blood lymphocytosis), is proposed. Clear-cut differences in the 10 year progression-free survival (PFS) were observed among patients scoring 0 (low risk), 1 (intermediate risk), 2?–?3 (high risk): 67.8, 41.0 and 24.8%, respectively (P<0.0001). The results of the Medical Research Council (MRC) suggesting a better clinical outcome for females prompted us to verify such a gender-related difference within our prognostic categories. Because changes in PFS only reflected gender for patients scoring 0 (P?=?0.04), the following prognostic subgroups are proposed: (1) females scoring 0; (2) males scoring 0; (3) patients scoring 1?–?3 whatever gender (10 year PFS: 76.2, 61.4 and 37.8%; P<0.00001). Our long-term database provides an adequate patient sample to generate a generalized risk stratification model based on clinical data. The indolent clinical outcome of women with early CLL is also supported by the higher frequency of the immunoglobulin heavy-chain variable (IgVH) mutational status and lower proportion of 17p and 11q deletions found in such a patient subset in the MRC CLL4 trial. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

71. Incidence of Early Adverse Events in Primary Myelofibrosis (PMI). a Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN

Author

Di Veroli, Ambra, Rossi, Elena, Breccia, Massimo, De Muro, Marianna, Villivà, Nicoletta, Trawinska, Malgorzata Monika, Crescenzi Leonetti, Sabrina, Montanaro, Guido, Romano, Atelda, Petriccione, Luca, D'Addosio, Ada, Centra, Antonia, Rauco, Annamaria, Anaclerico, Barbara, Abruzzese, Elisabetta, Maurillo, Luca, Carmosino, Ida, Montanaro, Marco, Andriani, Alessandro, De Stefano, Valerio, Foa, Robin, and Latagliata, Roberto

Abstract

Background.Adverse events are relatively more common in the follow-up of primary myelofibrosis (PMI) than in other Ph- myeloproliferative neoplasms, with higher morbidity and mortality rates, as reported in several retrospective studies. At present, however, prospective data on the early incidence (<4 years from diagnosis) of these complications in PMI are not available.

Published
2017
Full Text
View/download PDF

72. Primary Myelofibrosis in Younger Patients: A Retrospective Analysis of the Gruppo Laziale MPN Ph-Negative

Author

Breccia, Massimo, Di Veroli, Ambra, De Muro, Marianna, Trawinska, Malgorzata Monika, Crescenzi Leonetti, Sabrina, Cedrone, Michele, Petriccione, Luca, Romano, Atelda, D'Addosio, Ada, Molica, Matteo, Centra, Antonia, Porrini, Raffaele, Felici, Stefano, Maurillo, Luca, Montanaro, Marco, Andriani, Alessandro, Niscola, Pasquale, Foa, Robin, and Latagliata, Roberto

Abstract

Primary myelofibrosis (PMF) is a rare disorder commonly diagnosed in the 6th-7thdecade of life. In this retrospective study, we analyzed the clinical features at presentation of patients aged <50 years with a WHO-based diagnosis of primary PMF and compared them with those of the older cohort.

Published
2017
Full Text
View/download PDF

73. Possible Role Of Treatment On Secondary Malignancies In Patients Affected By Essential Thrombocytemia

Author

Santoro, Cristina, Di Giandomenico, Jonny, De Muro, Marianna, Villivà, Nicoletta, Di Veroli, Ambra, Montanaro, Marco, Latagliata, Roberto, Anaclerico, Barbara, Avvisati, Giuseppe, Breccia, Massimo, Cedrone, Michele, Cimino, Giuseppe, Montanaro, Guido, Montefusco, Enrico, Felici, Stefano, Crescenzi, Sabrina Leonetti, Majolino, Ignazio, Porrini, Raffaele, Rago, Angela, Spadea, Antonio, Spirito, Francesca, Alimena, Giuliana, Mazzucconi, Maria Gabriella, and Andriani, Alessandro

Abstract

Survival of Essential Thrombocytemia (ET) patients in the first 10 years of disease follow-up is similar to the general population one. While it is well known that alkylating agents (given alone or sequentially) increase the risk for acute myeloid leukemia, the specific role of different therapies on the development of secondary malignancies (SM) in ET patients, is still under investigation.

Published
2013
Full Text
View/download PDF

74. Azacitidine In The Treatment Of Ph- Myeloproliferative Neoplasms In Blastic Phase: The Experience Of Gruppo Laziale For The Study Of Ph- SMPC

Author

Andriani, Alessandro, Latagliata, Roberto, Voso, Maria Teresa, Villivà, Nicoletta, Ciccone, Fabrizio, Andrizzi, Cristina, De Gregoris, Cinzia, Buccisano, Francesco, De Blasio, Angelo, Anaclerico, Barbara, Avvisati, Giuseppe, Bagnato, Antonino, Cedrone, Michele, Cimino, Giuseppe, Majolino, Ignazio, Montefusco, Enrico, Spadea, Antonio, Alimena, Giuliana, and Montanaro, Marco

Abstract

Prognosis of patients with myeloproliferative neoplasms developing blast phase (MPN-BP) is very poor. Median survival of these patients is about 2-3 months (Cervantes F, Acta Hemathol 1991; Mesa RA, Blood 2005; Kantajian HM, Leukemia 1997; Tam CS, Blood 2008) and nowadays no drug can induce a durable complete response (CR) in patients who are not candidate to BMT. A phase II study (Thepot S., Blood 2010, 116, 3735) recently reported on 54 patients with MPN-BP treated with 5-AZA, showing a median survival of 9 months with an Overall Response Rate (ORR) of 52% (24% complete response).

Published
2013
Full Text
View/download PDF

75. MPT VsThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study.

Author

Offidani, Massimo, Bringhen, Sara, Corvatta, Laura, Petrucci, Maria Teresa, Gentili, Silvia, Musto, Pellegrino, Polloni, Claudia, Gentilini, Fabiana, Falcone, Antonietta, Caravita, Tommaso, Liberati, Anna Marina, Brunori, Marino, Callea, Vincenzo, Piro, Eugenio, Grasso, Mariella, Cangialosi, Clotilde, Galieni, Piero, Rossini, Fausto, Galli, Monica, Montanaro, Marco, Alesiani, Francesco, Stefano, Valerio De, Catarini, Massimo, Elice, Francesca, Zambello, Renato, Visani, Giuseppe, Griso, Luciano, Angelucci, Emanuele, Boccadoro, Mario, Leoni, Pietro, and Palumbo, Antonio

Abstract

Abstract 1835

Published
2009
Full Text
View/download PDF

76. Melphalan 200 Mg/m2(Mel200) VersusMelphalan 100 Mg/m2(Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study

Author

Boccadoro, Mario, Bringhen, Sara, Petrucci, Maria Teresa, Falcone, Antonietta, Liberati, Anna Marina, Ria, Roberto, Grasso, Mariella, Montanaro, Marco, Pregno, Patrizia, Nozza, Andrea, Pisani, Francesco, Caravita, Tommaso, Cangialosi, Clotilde, Calabrese, Elisabetta, Larocca, Alessandra, Cavallo, Federica, Ruggeri, Marina, Musto, Pellegrino, Foà, Robert, and Palumbo, Antonio

Abstract

Background.Several trials have shown the superiority of high-dose melphalan (usually 200 mg/m2, MEL200) versus standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) was also superior to the standard dose, but MEL100 has not been clinically compared with MEL200 in a randomized study. In this prospective, randomized, phase III trial, we compared the efficacy and toxicity of MEL200 and MEL100.

Published
2008
Full Text
View/download PDF

77. A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2(Mel200) Versus Melphalan 100 mg/m2(Mel100) in Newly Diagnosed Myeloma Patients.

Author

Palumbo, Antonio, Bringhen, Sara, Petrucci, Maria Teresa, Falcone, Antonietta, Liberati, Anna Marina, Lauta, Vito Michele, Grasso, Mariella, Montanaro, Marco, Pisani, Francesco, Caravita, Tommaso, Cangialosi, Clotilde, Pregno, Patrizia, Nozza, Andrea, Calabrese, Elisabetta, Gay, Francesca, Cavallo, Federica, Omedè, Paola, Musto, Pellegrino, Foà, Robin, and Boccadoro, Mario

Abstract

Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m2, MEL200) versus standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m2, MEL100) was also superior to the standard dose, but MEL100 has not been clinically compared with MEL200 in a randomized study. In this prospective, randomized, phase III trial, we compared the efficacy and toxicity of MEL200 and MEL100. The primary end points were complete remission (CR) rate, event-free survival (EFS) and incidence of gastrointestinal toxicity, infections and treatment-related mortality (TRM). Inclusion criteria were previously untreated myeloma, aged ≤ 65 and Durie and Salmon stage II or III. Exclusion criteria were abnormal pulmonar, cardiac, liver and renal function, HBV, HCV, or HIV positivity, concomitant cancer or psychiatric disease. The institutional review board approved the protocol and written informed consent was obtained from all patients. All patients received 2 cycles of 28-day-dexamethasone-doxorubicin-vincristine (doxorubicin 50 mg/m2day 1, vincristine 1 mg day 1, dexamethasone 40 mg days 1–4) and 2 cycles of cyclophosphamide (4 g/m2, day 1) followed by stem cell harvest. MEL200 patients was conditioned with 2 cycles of melphalan 200 mg/m2and MEL100 patients with 2 courses of melphalan 100 mg/m2, both followed by stem cell reinfusion. Two-hundred and ninety-eight patients (median age 57) were randomized, 149 to MEL200 and 149 to MEL100. All patients were evaluated for response, EFS and OS. Patient characteristics were similar in both groups. Chromosomal 13 was deleted in 69% of MEL200 and 45% of MEL100 patients (p=0.015). Ninety-six patients completed tandem MEL200; 103 tandem MEL100. In intention-to-treat analysis, the very good partial response rate was higher in MEL200 group (37% versus 21%, p=0.003), but CR was 15% in the MEL200 group and 8% in the MEL100 group (p=0.07). After a median follow-up of 30.5 months, the 3-years EFS was 46% in the MEL200 and 26% in the MEL100 group (HR=0.7, 95% CI 0.51–0.97, p=0.03). The 3-years overall survival (OS) was 81% in the MEL200 and 73% in the MEL100 group (HR=0.69, 95% CI 0.42–1.13, p=0.14). Duration of grade 4 neutropenia and thrombocytopenia was comparable, but a higher proportion of MEL200 patients required platelet transfusions (p=0.002). Grade 3–4 non-hematologic adverse events were more frequent in the MEL200 patients (38% versus 19%, p<0.0001). The incidence of grade 3–4 mucositis was 16% after MEL200 and 3% after MEL100 (p<0.0001). The incidence of severe gastrointestinal toxicity was 19% after MEL200 and 2% after MEL100 (p<0.0001). The incidence of grade 3–4 infections and of TRM was similar in both groups. In conclusion, MEL200 resulted in a significantly higher very good partial response rate. This translated in a superior EFS, but not OS.

Published
2007
Full Text
View/download PDF

78. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.

Author

Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, and Rapicetta M

Subjects
Antibodies, Viral blood, Case-Control Studies, Hepatitis B epidemiology, Hepatitis B Surface Antigens blood, Hepatitis C complications, Hepatitis C epidemiology, Hepatitis C Antibodies blood, Humans, Lymphoma, B-Cell complications, Lymphoma, B-Cell epidemiology, Lymphoma, B-Cell etiology, Prevalence, Hepatitis B complications, Lymphoma, B-Cell virology
Abstract

In this hospital-based, multicenter case-control study we investigated the prevalence of hepatitis B virus (HBV)-related markers and HBV/hepatitis C virus (HCV) co-infection among B-cell non-Hodgkin's lymphoma (B-NHL) cases and controls. Four hundred newly diagnosed B-NHL cases and 392 controls from other departments of the same hospitals were studied. The prevalence of positivity for hepatitis B surface antigen (HBsAg) was 8.5% among B-NHL cases and 2.8% among controls (adjusted odds ratio, 3.67; 95% confidence interval, 1.75-7.66). HBV/HCV co-infection was found in four cases, but in no controls. The finding of a positive association between HBV infection and B-NHL raises the possibility that HBV may play an etiologic role in the induction of B-NHL.

Published
2006

79. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.

Author

Bianco E, Marcucci F, Mele A, Musto P, Cotichini R, Sanpaolo MG, Iannitto E, De Renzo A, Martino B, Specchia G, Montanaro M, Barbui AM, Nieddu R, Pagano L, Rapicetta M, Franceschi S, Mandelli F, and Pulsoni A

Subjects
Acute Disease, Adolescent, Adult, Aged, Case-Control Studies, Female, Hepacivirus immunology, Hepacivirus isolation & purification, Hepatitis C Antibodies blood, Hodgkin Disease blood, Hodgkin Disease virology, Humans, Leukemia, Lymphocytic, Chronic, B-Cell blood, Leukemia, Lymphocytic, Chronic, B-Cell virology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood, Leukemia, Myelogenous, Chronic, BCR-ABL Positive virology, Leukemia, Myeloid blood, Leukemia, Myeloid virology, Lymphoma, B-Cell blood, Lymphoma, T-Cell blood, Lymphoma, T-Cell virology, Lymphoproliferative Disorders blood, Male, Middle Aged, Multiple Myeloma blood, Multiple Myeloma virology, Myeloproliferative Disorders blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma virology, Hepatitis C epidemiology, Lymphoma, B-Cell virology, Lymphoproliferative Disorders virology, Myeloproliferative Disorders virology
Abstract

Background and Objectives: Infection with hepatitis C virus (HCV) is associated with type II mixed cryoglobulinemia (MC), a lymphoproliferative disorder which, in some patients, evolves into overt B-cell non-Hodgkin's lymphoma (B-NHL). Recently, also the association between HCV infection and B-NHL, which had long been controversial, was confirmed in a large case-control study. Little knowledge is, however, available on possible associations between HCV infection and other lymphoid or myeloid malignancies. The present study was set up in order to investigate this aspect., Design and Methods: The study was conducted in hematology departments of ten hospitals in different Italian cities. The cases consisted of consecutive patients with a new diagnosis of T-NHL, Hodgkin's disease (HD), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The controls were patients in other departments of the same hospitals. HCV infection was investigated by testing for HCV antibodies and HCV-RNA in serum samples., Results: The prevalence of HCV infection was not higher in patients with HD (3.2%, 5 out of 157 cases) or MM (4.7%, 5 out of 107) than in controls. On the other hand, it was consistently higher in T-NHL (13.8%, 4 out of 30), CLL (9.0%, 9 out of 100), ALL (7.6%, 5 out of 54), AML (7.9%, 11 out of 140), and CML (12.2%, 6 out of 49) patients. These patient groups were not, however, large enough to render statistically significant results., Interpretation and Conclusions: Our data suggest that HCV infection may be associated not only with B-NHL but also with some other lymphoid and myeloid malignancies.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results